The UK and US have hammered out a major commercial pact that will maintain zero import taxes on UK drug shipments entering the American market.
The Terms of the Deal
As part of the deal, the UK has committed to raise expenditure on medicines through the public health system. This pledge ensures that duties on these vital goods will remain at nothing for a period of 36 months.
This development follows previous statements to hike import taxes on patented drug products, with increases floated up to one hundred percent.
"This arrangement with the Britain strengthens the worldwide climate for cutting-edge drugs and brings much-needed fairness to American-British pharmaceutical trade," an announcement declared.
Economic Significance
Medicines are one of the Britain's most significant export categories to the America, which is easily the biggest market for leading British pharmaceutical firms.
Statistics show that in the year prior to last September, the UK exported medicines valued at over eleven billion pounds to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This deal secures jobs, increases funding and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key UK Commitments
The agreement includes several notable commitments from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it considers new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at 15%. Last year, rebates were more than 20%.
Broader Context
This agreement comes amid a long-running tension between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
These tensions were exacerbated by assertions that American patients were charged significantly more for the same drugs than patients in the other developed nations.
Recently, several large manufacturing plans in the UK have been delayed or abandoned, while major investments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
